chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Introduction

  • Also known as chronic myelogenous, myelocytic, or chronic granulocytic leukemia
  • Has three phases: chronic, accelerated & blast
  • Median age at presentation is at >50 years old

Definition

  • A myeloid disorder associated with Philadelphia (Ph) chromosome t(9;22)(q34;q11), a fusion of the breakpoint cluster region (BCR) & Abelson murine leukemia (ABL1) genes

Signs and Symptoms

  • Systemic symptoms:
    • Anemia
    • Abdominal fullness
    • Abdominal pain that may present with left upper quadrant pain & early satiety
    • Bleeding episodes due to platelet dysfunction
    • Fatigue
    • Malaise
    • Weight loss
  • Other frequent findings:
    • Splenomegaly
    • Platelet count raised
    • White blood cell (WBC) count increased
    • Involvement of lymph nodes, skin & soft tissue (patients with blast crisis)

Risk Factors

  • The only known risk factor is exposure to ionizing radiation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 13 Feb 2020

Immunotherapy-chemotherapy combinations, immunotherapy doublets, and combinations of immunotherapy with novel targeted agents are emerging as strategies for management of metastatic urothelial carcinoma (mUC) in view of the limitations with chemotherapy and single-agent immunotherapy, said an expert at the Uro-Oncology Asia 2020 conference. 

Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM.